Department of Nephrology, Juntendo University Faculty of Medicine, Japan.
Department of Human Pathology, Juntendo University School of Medicine, Japan.
Intern Med. 2022 Apr 1;61(7):1033-1037. doi: 10.2169/internalmedicine.8787-21. Epub 2022 Feb 1.
A 28-year-old woman experienced gross hematuria after the administration of the second dose of an messenger ribonucleic acid (mRNA) vaccine (BNT162b2). She was diagnosed with Immunogloblin A nephropathy (IgAN) by a renal biopsy two weeks after vaccination, which revealed a mild increase in mesangial cells and a matrix with co-depositions of galactose-deficient IgA1 and C3 in the mesangial region. The gross hematuria and proteinuria gradually improved without any medication, suggesting that immune activation by the mRNA vaccine may not elicit continuous disease progression of IgAN. Thus, further studies investigating the relationship between mRNA vaccines against COVID-19 and the progression of IgAN should be conducted.
一名 28 岁女性在接种第二剂信使核糖核酸(mRNA)疫苗(BNT162b2)后出现肉眼血尿。两周后肾活检诊断为免疫球蛋白 A 肾病(IgAN),显示系膜细胞轻度增加,伴系膜区半乳糖缺乏 IgA1 和 C3 共沉积的基质。肉眼血尿和蛋白尿逐渐改善,无需任何药物治疗,表明 mRNA 疫苗引起的免疫激活可能不会引起 IgAN 的持续疾病进展。因此,应进一步研究针对 COVID-19 的 mRNA 疫苗与 IgAN 进展之间的关系。